• 基本信息
    导师姓名： 沈坤炜 学科代码： 100210
    性别： 男 学科名称： 外科学
    培养单位： 附属瑞金医院 三级学科 普外
    导师类型： 博士生导师 专业领域名称： 外科学 专业学位
    联系方式： kwshen@medmail.com.cn 专业领域代码： 105111
    邮编： 200025 邮箱地址： kwshen@medmail.com.cn
  • 研究方向 (点击浏览详细信息)
  • 社会任职
     
    上海交通大学乳腺疾病诊治中心主任
  • 科研项目
    项目编号项目名称课题来源起止年月批准经费承担职责
    82072897受体酪氨酸激酶EPHA3 调控 HER2 蛋白稳定性介导 HER2 阳性乳腺癌细胞曲妥珠单抗治疗耐药的作用及机制研究国家自然科学基金 2021-01~2024-12 55万元  课题负责人
    81772797乳腺癌微环境中CAF分泌的外泌体递送相关LncRNA介导曲妥珠单抗治疗耐药的研究国家自然科学基金面上项目 2018-01~2021-12 50万元  课题负责人
    DLY201508紫杉醇±卡铂在三阴性乳腺癌辅助化疗中的临床与疗效预测研究上海交通大学医学院 2015-12~2017-12 100万元  课题负责人
    15411952500基于乳腺癌数据共享平台的临床诊疗信息分析上海市科委重点学科“科技创新行动计划” 2015-07~2018-09 50万元  课题负责人
    联合靶向抑制CDK4/6和PI3K/Akt/mTOR 通路在ER阳性乳腺癌治疗中的作用横向课题 2015-06~2018-05 10万元  课题负责人
    81472462白介素-6激活乳腺癌糖酵解代谢通路与曲妥珠单抗耐药的研究国家自然科学基金面上项目 2015-01~2018-12 76万元  课题负责人
    SHDC12014103多基因阵列分析技术在中国Luminal 型乳腺癌规范化个体治疗中的研究上海申康医院发展中心新兴前沿技术项目 2014-10~2017-09 150万元  课题负责人
    14411950200Luminal型乳腺癌个体化内分泌治疗模式的研究上海市科委重点学科“科技创新行动计划 2014-07~2017-09 300万元  课题负责人
    320.6750.12284中国女性乳腺癌患者PI3K/Akt/mTOR信号传导通路状态检测的研究吴阶平医学基金会 2012-12~2014-12 20万元  课题负责人
    12140901503基于中国人群的原代人源乳腺癌移植瘤模型的建立与研究上海市科委重点课题子课题 2012-11~2014-09 15万元  子课题负责人
     Exploring the Effect of Targeting PI3K-Akt-mTOR Pathway in Treatment of Chinese Triple Negative Breast Cancer Patients横向课题 2012-10~2014-10 20万元  课题负责人
    81172520Lapatinib耐药与乳腺癌上皮间质转化相关信号传导通路关系的研究国家自然科学基金 2012-01~2015-12 56万元  课题负责人
     基础临床交叉团队（乳腺癌）985三期建设项目 2011-10~2012-10 40万元  子课题负责人
    320.6700.09075循环肿瘤细胞在乳腺癌新辅助化疗中的动态变化及其与疗效的关系吴阶平医学基金会 2010-02~2011-02 10万元  主要责任人
    09411961400药物对乳腺癌干细胞靶向治疗作用的研究上海市科委 2009-07~2012-06 10万元  课题负责人
    J50208乳腺癌的临床研究和基础转化型研究上海市教委重点学科—肿瘤学 2009-07~2012-12 320万元  子课题负责人
     Targeting mTOR and PI3K with RAD001 in breast cancer treatment横向课题 2009-06~2012-12 30万元  主要责任人
    多西他赛联合蒽环类药物和环磷酰胺（TAC）或多西他赛联合环磷酰胺（TC）新辅助治疗三阴性或HER2阳性的乳腺癌临床研究横向课题 2009-03~2013-06 400万元  课题负责人
  • 学术论文
    作者论文标题期刊名出版年卷期页码
    Ding S, Sun X, Lu S, Wang Z, Chen X,  Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer.  Breast.  2021  57:71-79. 
    Tong Y, Gao W, Wu J, Zhu S, Huang O, He J, Zhu L, Chen W, Li Y,, Chen X.  Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients.  Front Oncol.  2021  11:619840. 
    Lu Y, Tong Y, Chen X,  Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients.  Front Oncol.  2021  11:638619.  
    Sun X, Wang Z, Chen X,  CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer.  Front Cell Dev Biol.  2021  9:646774. 
    Li S, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients.  BMC Cancer  2021  21(1):807.  
    Sun X, Ding S, Lu S, Wang Z, Chen X,  Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer.  Onco Targets Ther.  2021  14:3611-3624.  
    Zhu S, Li Y, Chen W, Fei X,, Chen X.  Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment.  Front Oncol.  2021  11:636266. 
    Hong J, Tong Y, He J, Chen X,  Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery.  Ther Adv Med Oncol  2021  13:1758835921996673. 
    Dong S, Wang Z,, Chen X.  Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis.  Front Oncol.  2021  11:629666.  
    Yu J, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age.  J Transl Med.  2021  19(1):75.  
    Yu J, Lin C, Huang J, Hong J, Gao W, Zhu S, Lin L, Chen X, Huang O, He J, Zhu L, Chen W, Li Y, Wu J,  Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer.  BMC Cancer  2021  21(1):707. 
    Sun X, Zhou ZR, Fang Y, Ding S, Lu S, Wang Z, Wang H, Chen X,  A novel metabolic gene signature-based nomogram to predict overall survival in breast cancer.  Ann Transl Med.  2021  9(5):367.  
    Zeng Y, Gao W, Chen X,  Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.  Br J Cancer.  2021  124(5):975-981. 
    Montagna G, Tong Y, Ritter M, Levi J, Weber WP, Chen X,  Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer.  Oncology.  2021  99(6):359-364.  
    Hong J, Huang J, Shen L, Zhu S, Gao W, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.  BMC Cancer.  2020  20(1):663. 
    Hong J, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis.  J Cancer.  2020  11(23):6916-6924. 
    Su J, Yu B, Zhang C, Yi P, Li H, Xu C, Cao L, Chen P, Li M,, Chen J.  Long noncoding RNA HOXC-AS3 indicates a poor prognosis and regulates tumorigenesis by binding to YBX1 in breast cancer.  Am J Transl Res.  2020  12(10):6335-6350. 
    Zhu Y, Wang T, Wu J, Huang O, Zhu L, He J, Li Y, Chen W, Chen X,  Associations Between Circulating Insulin-Like Growth Factor 1 and Mortality in Women With Invasive Breast Cancer.  Front Oncol.  2020  10:1384. 
    Yu J, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.  Oncol Lett.  2020  20(2):1545-1556. 
    Wang Z, Wang H, Ding X, Chen X,  A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer.  Ther Adv Med Oncol.   2020  12:1758835920932674. 
    Yu J, Wu J, Huang O, He J, Li Z, Chen W, Li Y, Chen X,  Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?  Front Oncol.  2020  10:708.  
    Lu Y, Tong Y, Huang J, Lin L, Wu J, Fei X, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients.  Front Oncol.  2020  10:1315. 
    Wang Z, Li TE, Chen M, Pan JJ,  miR-106b-5p contributes to the lung metastasis of breast cancer via targeting CNN1 and regulating Rho/ROCK1 pathway.  Aging (Albany NY)  2020  12(2):1867-1887. 
    Zeng Y, Gao W, Lin L, Chen X,  Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer.  J Geriatr Oncol  2020  ;11(5):843-849. 
    Wang Z, Chen M, Pan J, Wang X, Chen XS,  Pattern of distant metastases in inflammatory breast cancer - A large-cohort retrospective study.  J Cancer.  2020  11(2):292-300. 
    Wang H, Yao J, Zhu Y, Zhan W, Chen X,  Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.  Cancer Med.   2020  9(17):6173-6185.  
    Gao W, Lin L, Fei X, Chen X,  Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score.  J Cancer.  2020  11(9):2509-2517.  
    Wang Z, Wang H, Sun X, Fang Y, Lu SS, Ding SN, Chen XS,  A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients With de novo Distant Metastasis.  Front Oncol.  2020  10:14. 
    Fang Y, Wang Z, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients.  J Cancer.  2020  11(9):2602-2609.  
    Wang H, Zhan W, Chen W, Li Y, Chen X,  Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer.  Breast  2020  49:33-40.  
    Li S, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab.  Breast.  2020  54:235-241. 
    Gao Y, Chen X, He Q, Gimple RC, Liao Y, Wang L, Wu R, Xie Q, Rich JN,, Yuan Z.  Adipocytes promote breast tumorigenesis through TAZ-dependent secretion of Resistin.  Proc Natl Acad Sci U S A.  2020  117(52):33295-33304. 
    Gao W, Zeng Y, Fei X, Chen X,  Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis.  Breast Cancer Res Treat.  2020  184(1):193-202. 
    Tong Y, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients.  Front Oncol.  2020  10:550.  
    Wu J, Gao W, Chen X, Fei C, Lin L, Chen W, Huang O, Zhu S, He J, Li Y, Zhu L,  Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients.  Front Med.  2020  epub 
    Zhu Y, Wang T, Wu J, Huang O, Zhu L, He J, Li Y, Chen W, Chen X,  Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast Cancer Risk in Chinese Women.  Onco Targets Ther.  2020  13:8027-8036. 
    Ding S, Chen X,  Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy.  Cancer Commun (Lond).  2020  40(8):329-344.  
    Wang G, Qin S, Zayas J, Ingle JN, Liu M, Weinshilboum RM,, Wang L.  4-Hydroxytamoxifen enhances sensitivity of estrogen receptor alpha-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.  Breast Cancer Res Treat.  2019  175(3):567-578. 
    Tong Y, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X,  21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.  Sci Rep.   2019  9(1):13123.  
    Liang Y, Chen X, Tong Y, Zhan W, Zhu Y, Wu J, Huang O, He J, Zhu L, Li Y, Chen W,  Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era  World J Surg Oncol  2019  17(1):37 
    Tong YW, Wang G, Wu JY, Huang O, He JR, Zhu L, Chen WG, Li YF, Chen XS,  Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy.  Onco Targets Ther.  2019  12:3977-3989.  
    Wang W, Lin L, Fei X, Hong J, Gao W, Zhu S, Wu J, Huang O, He J, Li Y, Zhu L, Chen W, Chen X,  21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.  Oncol Lett.  2019  18(4):4346-4356. 
    Hong J, Chen X, Gao W, Zhu S, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Fei X, Lin L,  A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab.  Cancer Manag Res.  2019  11:3371-3379.  
    Zhu S, Wu J, Huang O, He J, Zhu L, Li Y, Chen W, Fei X, Chen X,  Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample.  Ann Surg Oncol.  2019  26(9):2779-2786. 
    Huang J, Chen X, Fei X, Huang O, Wu J, Zhu L, He J, Chen W, Li Y,  Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study  Cancer Res Treat.  2019  51(4):1336-1346.  
    Wang W, Chen X, Lin L, Fei X, Garfield DH, Hong J, Gao W, Zhu S, Wu J, Huang O, He J, Li Y, Zhu L, Chen W,  Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study  J Cancer  2018  9(18):3216-3224 
    Qu F, Chen X, Fei X, Lin L, Gao W, Zong Y, Wu J, Huang O, He J, Zhu L, Chen W, Li Y,  A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score.  Chin J Cancer Res.  2018  30(2):222-230.  
    Wang G, Chen X, Liang Y, Wang W, Fang Y,  Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen  J Breast Cancer  2018  21(3):277-287 
    Tong Y, Chen X, Fei X, Lin L, Wu J, Huang O, He J, Zhu L, Chen W, Li Y,  Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?  Eur J Cancer  2018  89:9-18. 
    Wu J, Fang Y, Lin L, Fei X, Gao W, Zhu S, Zong Y, Chen X, Huang O, He J, Zhu L, Chen W, Li Y,  Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.  Oncotarget  2017  8(24):38706-38716 
    Wang G, Chen X, Wang W,  A long non-coding RNA signature that predicts pathological complete remission rate sensitively in neoadjuvant treatment of breast cancer  Transl Oncol  2017  10(6):988-997. 
    Lu S, Wu J, Fang Y, Wang W, Zong Y, Chen X, Huang O, He JR, Chen W, Li Y,, Zhu L.  The impact of surgical excision of the primary tumor in stage IV breast cancer on survival: a meta-analysis  Oncotarget   2017  9(14):11816-11823. 
    Liang Y, Chen X, Zhan W, Garfield DH, Wu J, Huang O, Li Y, Zhu L, Chen W,  Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease?  Ann Surg Oncol  2017  24(7):1874-1880. 
    Hong J, Chen X, Huang J, Li C, Zhong L, Chen L, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Wan H,  Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study  Integr Cancer Ther  2017  16(3):406-413. 
    Zong Y, Wu J,  Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis  Oncotarget  2017  7;8(10):17360-17372. 
    Chen X, Ye G, Zhang C, Li X,  Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study.  Chin J Cancer Res.  2016  28(6):561-569. 
    Liu J, Chen X, Ward T, Mao Y, Bockhorn J, Liu X, Wang G, Pegram M,  Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer  Int J Biochem Cell Biol  2016  71:12-23. 
    Hong J, Mao Y, Chen X, Zhu L, He J, Chen W, Li Y, Lin L, Fei X,  Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer  Tumor Biology   2016  37(3):4135-42 
    Huang O, Wu D, Zhu L, Li Y, Chen W,  Concurrent adjuvant radiochemotherapy versus standard chemotherapy followed by radiotherapy in operable breast cancer after breast conserving therapy: A meta-analysis.  Journal of Cancer Research and Therapeutics   2016  12(1):84-89 
    Mao Y, Zhang Y, Qu Q, Zhao M, Lou Y, Liu J, Huang O, Chen X, Wu J,  Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells.  Mol Biosyst.   2015  11(4):1029-40. 
    Qu Q, Mao Y, Xiao G, Fei X, Wang J, Zhang Y, Liu J, Cheng G, Chen X, Wang J,  USP2 promotes cell migration and invasion in triple negative breast cancer cell lines.  Tumour Biol.  2015  36(7):5415-23. 
    Huang O, Jiang M, Chen XS, Wu JY, Chen WG, Li YF,  Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.  Cell Biochem Biophys  2015  71(2):1181-90. 
    Chen X, Zhu S, Fei X, Garfield DH, Wu J, Huang O, Li Y, Zhu L, He J, Chen W, Jin X,  Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.  BMC Cancer.   2015  5:822 
    Huang O, Jiang M, Zhang X, Chen X, Wu J,  FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis.  Tumour Biol.  2014  35(2):1089-94. 
    Jiang M, Huang O, Xie Z, Wu S, Zhang X, Shen A, Liu H, Chen X, Wu J, Lou Y, Mao Y, Sun K, Hu S, Geng M*,  A novel long non-coding RNA-ARA: Adriamycin Resistance Associated.  Biochem Pharmacol  2014  87(2): 254-83. 
    Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O,  Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.   PLoS One.  2014  9(9):e108405 . 
    Zong Y, Zhu L, Wu J, Chen X, Huang O, Fei X, He J, Chen W, Li Y,  Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study.  PLoS One.  2014  9(8):e95629.  
    André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M,, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L.  Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.  Lancet Oncol  2014  15(6):580-91 
    Mao Y, Qu Q, Zhang Y, Liu J, Chen X,  The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.   PLoS One.  2014  9(12):e115103. 
    Wu JY, Chen WG, Chen XS, Huang O, He JR, Zhu L, Li Y,  Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy.  Mol Clin Oncol.  2014  2(6):997-1002.  
    Wu JY, Chen WG, Chen XS, Huang O, He JR, Zhu L, Li Y,, Chow LW, Loo WT, Chow CY, Tsang W.  Outcomes of adjuvant endocrine therapy and hormone receptor status change following neoadjuvant chemotherapy in breast cancer patients.  Int J Biol Markers.  2014  29(4):e380-6.  
    Qu Q, Zong Y, Fei XC, Chen XS, Xu C, Lou GY,  The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer.  World J Surg Oncol  2014  12:93. 
    Huang O, Xie Z, Zhang W, Lou Y, Mao Y, Liu H, Jiang M,  A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine?resistant breast cancer cells.  Oncol Rep  2014  32(2):627-34. 
    Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, Wang J, Yuan F, Sun L, Yu Q, Jin X, Wang J,  PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.  Cancer Immunol Immunother  2014  63(4):395-406 
    Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M,  Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.  PLoS One  2013  8(8):e72053. 
    Mao Y, Keller ET, Garfield DH,, Wang J.  Stromal cells in tumor microenvironment and breast cancer.  Cancer Metastasis Rev  2013  32(1-2):303-15 
    Qu Q, Mao Y, Fei XC,  The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis.  PLoS One  2013  8(12):82650-1 
    Chen X, Sun L, Mao Y, Zhu S, Wu J, Huang O, Li Y, Chen W, Wang J, Yuan Y, Fei X, Jin X,  Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.  Mol Cancer Res  2013  11(10):1269-78. 
    Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, Geng M,  Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9.  Molecules  2013  18(1):701-20. 
    Chen X, Sun L, Mao Y, Zhu S, Wu J, Huang O, Li Y, Chen W, Wang J, Yuan Y, Fei X, Jin X,  Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer.  BMC Cancer  2013  13:390. 
    Huang O, Jiang M, Zhang X, Xie Z, Chen X, Wu J, Liu H,  Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy.  Jpn J Clin Oncol  2013  43(11):1064-72 
    Chen X, Ye G, Zhang C, Li X, Chen Y, Xie X, Zheng H, Cao Y, Wu K, Ni D, Tang J, Wei Z,  Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.  Breast Cancer Res Treat  2013  142(3):549-58 
    Chen X, Yuan Y, Gu Z,  Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis  Breast Cancer Res Treat  2012  134(3):957-67. 
    Chen X, Wu J, Lu H, Huang O,  Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer  Cancer Sci  2012  103(2):262-8. 
    Yuan Y, Chen XS, Liu SY,  Accuracy of MRI in Prediction of Pathological Complete Remission in Breast Cancer after Preoperative Therapy: A Meta-analysis  AJR  2010  195(1):260-8. 
    Ma CD, Niu XQ, Luo JM, Shao ZM,  Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells  Cancer Sci  2010  101(10):2220-6 
    Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ,  Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer  Tumori  2010  96(1):103-110. 
    Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ,  Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy  Oncology Reports  2010  23(5):1213-20. 
    Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ,  Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.  Annals of Oncology  2010  21(5):961-967 
    Huang O, Chen C, Wu J, Chen S, Chen X, Liu G, Hu Z, Lu J, Wu J, Shao Z, Shen Z,  Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months  BMC Cancer  2009  9:375 
    Huang O, Wang L,, Lin H, Hu Z, Liu G, Wu J, Lu J, Shao Z, Han Q, Shen Z.  Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy.  Breast Cancer Res Treat  2008  107(3):379-87. 
    Ma CD, Chen CM, Chen XS, Liu GY, Di GH, Wu J, Lu JS, Yang WT, Chen JY, Shao ZM, Shen ZZ,  Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.  Anticancer Res  2008  28(5B):3093-7. 
    , Wu J, Lu JS, Han QX, Shen ZZ, Nguyen M, Shao ZM, Barsky SH.  Fiberoptic ductoscopy for patients with nipple discharge.  Cancer  2000  89(7):1512-9.